JP Morgan Chase’s PaxMedica, Inc. Common Stock PXMD Stock Holding History

JP Morgan Chase’s Portfolio PXMD Stock Details PXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,699	Closed	-$4.31K	–	8108
2023 Q4	$4.31K	Buy	+5,699	New	+$13.2K	﹤0.01%	6581
2023 Q3	–	Hold	0	–	–	–	7422

Other funds holding PXMD

SFA

Souders Financial Advisors Cincinnati, Ohio $876M AUM 14.39% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

JP Morgan Chase's PXMD Position: Q1 2024 in Review

JP Morgan Chase sold out of PaxMedica, Inc. Common Stock (PXMD) in Q1 2024, closing a stake of 5,699 shares — an estimated $4.31K sold.

JP Morgan Chase first reported a position in PXMD in Q4 2023 and held it in 1 quarter. The position peaked at $4.31K in Q4 2023. 8 funds tracked by Wall St. Rank hold PXMD as of Q1 2024.

JP Morgan Chase reported no remaining PaxMedica, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 5,699 PaxMedica, Inc. Common Stock shares in Q1 2024, an estimated $4.31K.
JP Morgan Chase first reported a position in PaxMedica, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
JP Morgan Chase's PaxMedica, Inc. Common Stock position peaked at $4.31K in Q4 2023.
8 funds tracked by Wall St. Rank held PaxMedica, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.